Form 8-K NEKTAR THERAPEUTICS For: Mar 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Sees Potential Nektar Therapeutics (NKTR) Takeover by Bristol-Myers Squibb (BMY) This Year
March 2, 2018 6:31 AM ESTMizuho Securities analyst Difei Yang believes there is a possibility of a Nektar Therapeutics (NASDAQ: NKTR) take-out in 2018 and new positive clinical data of NKTR-214 in combo with Bristol-Myers Squibb (NYSE: BMY) Opdivo reinforces their... More
